Shares of Biogen Idec, Celgene, Gilead Sciences, and Lexicon Pharmaceuticals recovered from last week's selloff.» Read More
Some of the names on the move ahead of the open.
April 3- Mylan Inc on Thursday sued Celgene Corp to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market.
Jim Cramer has noticed that many individual investors share a common fear.
Talk about a tempestuous affair. It looks like investors are again falling for stocks that they scorned just days ago.
After a rough patch last week where investors sold some of the market's hottest stocks, momentum names led a sharp rally in the Nasdaq on Tuesday.
The big issue for this quarter will be: will they economy pick up? The big debate for this quarter will be growth versus value.
There’s a vicious new trend underway in the market and Cramer says stocks of perfectly good companies could take a big hit.
Tesla looks like a good stock to buy on Monday's pullback, Brian Kelly of Brian Kelly Capital says.
A high-priced drug sold by Gilead Sciences is under lawmakers' scrutiny. But one analyst says there's a bigger problem.
March 21- U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs. Biogen Idec fell 8 percent, Amgen Inc dropped 3 percent and Celgene Corp lost 3.7 percent.
March 21- U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs. Biogen Idec fell 6 percent, Amgen Inc dropped 2.5 percent and Celgene Corp was down 2 percent.
Events in Ukraine appear to be improving, but it may only be a matter of time before they take another turn for the worse. Are you prepared?
In his book "Get Rich Carefully," CNBC's "Mad Money" host explains how spotting long-term megatrends can help investors surf the wave of profitability.
If there's a Holy Grail in the stock market, Cramer says it's got to be this.
Some of Thursday's midday movers:
Treasurys held on to earlier losses after of the Treasury Dept's auction of five-year notes and seven-year debt and after the release of US GDP data.
U.S. stock index futures traded higher on Thursday, on what will be the busiest day of fourth quarter earnings season.
Some of Tuesday's midday movers:
“These are the kind of stocks you can fall back on, in moments where the market gets clobbered,” said Cramer.
Traders are bracing for another rough ride in markets this week, as the emerging markets continue to shakeout and the Fed is expected to announce another round of cuts to its easing program.